Article
Eradicating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
2021-05-20
Abstract excerpt
<title>Abstract</title> <p>Leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) are quiescent, insensitive to BCR-ABL1 tyrosine kinase inhibitors (TKIs) and responsible for CML relapse. Therefore, eradicating quiescent CML LSCs is a major goal in CML therapy. Here, using a novel G0 marker (G0M), we narrowed down CML LSCs as G0M- and CD27- double positive cells among the conventional CML LSCs. Whole transc...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d0246d5c-52ba-5338-b609-527c90c45183
- DOI
- 10.21203/rs.3.rs-449398/v1
